• ATRIVA Therapeutics

    First-in-class host-targeting antiviral therapies against severe respiratory viral infections, including COVID-19 and influenza.


    Great potential against a wide range of respiratory viruses due to antiviral and immunomodulating activity of ATRIVA’s lead product ATR-002. Phase I clinical trial successfully completed, Phase II in COVID-19 cleared by German authorities, to start in early 2021. Phase II in influenza to start in H2 2021.


    Learn more


  • ATRIVA Therapeutics

    Invest in research to contribute to pandemic preparedness!


    We invite you to explore our approach and development milestones presented on this website and encourage you to contact us directly.


    Get in touch


  • 1
  • 2
  • ATRIVA Therapeutics

    First-in-class host-targeting antiviral therapies against severe respiratory viral infections, including COVID-19 and influenza.


    Learn more


  • ATRIVA Therapeutics

    Invest in research to contribute to pandemic preparedness!


    Get in touch
  • 1
  • 2

About Us

Learn more about the team behind
ATRIVA Therapeutics GmbH.

 

Read more

The ATRIVA Approach

Novel host-targeting approach to prevent viral replication.

 

Read more

Markets & Investors

Financing and business development
opportunities.

 

Read more

Press Releases

 

Read more

Media Coverage

 

Read more

Events & Presentations

 

Read more

  • News
  • Serial German biotech entrepreneur Dr. Ulrich Dauer appointed as new Chairman
  • Michael Grissinger to replace Emilie Hofstetter, adding pharmaceutical deal-making and US market expertise
  • Atriva Therapeutics is currently investigating its lead candidate ATR-002 in a Phase II trial against COVID-19

Tübingen and Frankfurt (Germany), January 20, 2021 – Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced changes to its Advisory Board. The Company appointed Dr. Ulrich Dauer as new Chairman of the Advisory Board succeeding co-founder Prof. Dr. Stephan Ludwig who will continue to serve on the Advisory Board of Atriva Therapeutics. Effective end of 2020, Emilie Hofstetter resigned from the Board. Michael Grissinger took over her position by Jan 1st, 2021.

“We would like to warmly thank Prof. Stephan Ludwig and Emilie Hofstetter for their strong commitment over the last years since the foundation of the Company and their advice in advancing Atriva’s scientific and corporate achievements to clinical trials. Prof. Ludwig will continue to offer his scientific insight and expertise as virologist in the Advisory Board, which are highly valuable for our future development,” said Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics, continuing: “With Dr. Ulrich Dauer and Michael Grissinger we were able to attract two accomplished sector specialists to our Advisory Board. Both have several decades of experience in the biotech and pharmaceutical industry. Their proven expertise in effectively managing biotech and pharmaceutical companies, leading transactions and forming strong collaborations will be invaluable as Atriva advances in clinical development, diversifying its later-stage clinical pipeline.”

Dr. Ulrich Dauer is a biotechnology entrepreneur and serial executive with long term experience and has been serving as Chief Executive Officer of Vivoryon Therapeutics N.V. since May 2018. Before that, he was CEO of Ventaleon GmbH and OMEICOS Therapeutics GmbH, founding CEO of 4SC AG, and Chief Strategy Officer at Activaero GmbH. His expertise focuses on successfully leading critical advances of biotech companies, including IPOs, financial and business transactions, partnerships and assembling clinical pipelines. Dr. Dauer received his PhD in natural sciences from Julius-Maximilians Universitaet Wuerzburg, Germany.

“I am excited to support Atriva, “said Dr. Ulrich Dauer, Chair of Atriva’s Advisory Board. “I have a special interest in the field of respiratory infections, particularly influenza, and am impressed by this new and innovative approach to antiviral treatment that Atriva is developing. If proven successful also in the later clinical phases, Atriva’s approach of stopping virus propagation by inhibiting necessary host cell factors could become the first true broad-band antiviral.”

Michael Grissinger is a senior executive with a proven track-record in key leadership roles in the pharmaceutical industry with a focus on pharmaceutical deal-making, strategy, and business development. Currently, he is serving on the Boards of Directors of several private and publicly traded biotech and pharmaceutical companies and advising a private equity firm. Before, he was at Johnson & Johnson for over 20 years, where he held several corporate vice-presidential roles focusing on global business development and licensing. His earlier career included positions at Ciba-Geigy, SmithKline Beckman, and Upjohn. He holds a Bachelor of Science (B.S.) in Chemistry from Juniata College, Huntingdon, Pennsylvania, USA, and a Master of Business Administration (M.B.A.) from Temple University – Fox School of Business in Philadelphia, USA.

“Atriva Therapeutics is at a critical development stage, advancing its clinical candidate into Phase II against COVID-19, the pandemic that is still keeping the world breathless,” said Michael Grissinger. “Looking ahead, securing pandemic preparedness will be crucial for humankind, and Atriva Therapeutics could play a central role in it. I am therefore more than happy to support the growth and future company development with my experience and to become part of this exciting story.”

Atriva’s Advisory Board consists of five members and two observers. In addition to Dr. Ulrich Dauer, Michael Grissinger and Prof. Stephan Ludwig there are two members who will continue to represent Atriva’s largest investors on the Board: Frans van Dalen and Paul Lelieveld represent the investor Meneldor. The two observers Frank Hensel, PhD, represent the Hightech-Gründer-Fonds Management GmbH and Rudolf Erlemann, PhD, sits for InSymbiosis.

Atriva Therapeutics has recently started a clinical Phase II trial investigating their lead candidate ATR-002 against moderate to severe COVID-19 in hospitalized patients. RESPIRE is a randomized, double-blind, Placebo-controlled study, which will be conducted at national and international study centers including Berlin-based Charité. ATR-002 is a small molecule developed against respiratory infection of RNA viruses.

About ATR-002’s mode of action with dual benefit

The Atriva lead product ATR-002 is developed specifically to treat diseases such as influenza and COVID-19, caused by RNA viruses. ATR-002 is a clinical stage MEK inhibitor drug candidate targeting the intracellular Raf/MEK/ERK signaling pathway. This pathway is central for replication of many RNA viruses, such as the influenza virus, hantavirus or respiratory syncytial virus (RSV) and also SARS-CoV-2, the virus that causes COVID-19. In influenza virus infected cells, the interaction of ATR-002 with MEK (MAPK/ERK kinase) prevents export of the viral genome protein complexes (ribonucleoprotein, RNP) from the nucleus to the cytoplasm, thus blocking the formation of functional new viral particles. This ultimately reduces the viral load in the body.[i]

In addition, ATR-002 has the potential to modulate the pro-inflammatory cytokine response of the body, avoiding overshooting cytokine response that can be caused by such viral infections. MEK inhibition can reduce the gene expression of some of the cytokines involved, like TNF-α, IL-1ß, IP-10, IL-8, MCP-1 and MIP-1a, and thus mitigate the overactive inflammatory response in the lungs of patients who are severely ill with influenza or COVID-19.[ii]

About Atriva Therapeutics GmbH

Atriva Therapeutics, founded in 2015, is a biopharmaceutical company pioneering the development of host-targeting antiviral therapies set up by a team of leading scientists in viral research and seasoned industry experts. The Company aims to develop a therapy platform to treat severe respiratory diseases induced by RNA viruses with a high unmet medical need, such as influenza and COVID-19. The Atriva lead product ATR-002 is a first-in-class host-targeting agent which inhibits viral replication in influenza and favorably modulates the body’s immune response. ATR-002 is under clinical development and has successfully completed a Phase I trial to demonstrate safety and tolerability in healthy subjects. The Company has obtained regulatory approval for a Phase II study to evaluate efficacy in hospitalized COVID-19 patients; a Phase II study in influenza is planned to start later in 2021. The Company owns eleven patent families with broad international coverage related to the use of MEK inhibitors and other kinase inhibitors for antiviral therapies. The patent life runs through 2041. Atriva Therapeutics is located in Tübingen and Frankfurt, Germany.

Atriva is a founding member of the BEAT-COV initiative. www.beat-cov.de

For further information, please visit www.atriva-therapeutics.com and follow us on LinkedIn and Twitter.

Contact:

Atriva Therapeutics GmbH
Dr. Rainer Lichtenberger, CEO
phone: +49 6196 56 11 698
mobile: +49 151 7443 3175
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media and Investor Relations:

MC Services AG
Eva Bauer / Raimund Gabriel
phone: +49 89 210 228 80
This email address is being protected from spambots. You need JavaScript enabled to view it.

 [i]     Pleschka S et al. Nat Cell Biol 2001 Feb 3:301-5; Planz O Antiviral Res 2013 Jun 98(3):457-68; Haasbach E et al. Antiviral Res 2017 Jun 142:178-4; Laure M et al. Antiviral Res 2020 Jun 178:104806.
[ii]     Pinto R et al. Antiviral Res 2011 Oct 92(1):45-56; Planz O Antiviral Res 2013 Jun 98(3):457-68; Schräder T et al. Antiviral Res 2018 Sep 157:80-92.

  • RESPIRE is a placebo-controlled, international, multi-center trial treating hospitalized patients with moderate to severe COVID-19
  • The Phase II clinical trial will evaluate efficacy, safety and pharmacokinetics of ATR-002, an orally available small molecule with a beneficial dual antiviral and immunomodulatory effect
  • Charité – Universitätsmedizin Berlin, and further German and international clinical trial sites to start enrollment of 220 patients

Tübingen and Frankfurt (Germany), January 5th, 2021 – Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, announced today approval from the German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) to initiate a pivotal Phase II clinical study with ATR-002 to treat hospitalized patients with moderate to severe COVID-19.

RESPIRE[1] is a randomized, double-blind, placebo-controlled, international, multi-center Phase II clinical trial in 220 adult patients with moderate to severe COVID-19, requiring hospitalization, but not requiring ICU admission or ventilator support at the time of screening or randomization. On top of standard of care, half the patients will receive ATR-002 900 mg, administered as tablets once daily on day 1, followed by ATR-002 600 mg once daily on days 2 to 6. Patients in the control group will receive placebo in a matching scheme, on top of standard of care.

Primary endpoint of the study is to prove the efficacy of ATR-002 versus placebo in addition to standard of care; secondary endpoints include the measurement of changes in clinical signs and symptoms and other relevant clinical parameters, scores, and study events. Outcomes will be assessed based on the clinical severity status on day 15, using a 7-point ordinal scale as suggested by the WHO COVID-19 Therapeutic Trial Synopsis.[2] All patients will be followed-up for 90 days. The study will also evaluate the pharmacokinetics of ATR-002.

The Atriva lead candidate ATR-002 is a small molecule developed specifically to treat respiratory viral infections by inhibiting MEK, a host cell factor required for the replication of various RNA viruses, including influenza virus and SARS-CoV-2. MEK also modulates cytokine and chemokine release. Due to this mode of action with a dual benefit, ATR-002 not only inhibits viral replication but could also prevent a cytokine storm and the associated disease progression to a life-threatening condition and, thus, reduce the resulting burden on hospitals and healthcare systems.[3]

“We are delighted to receive this approval from the German authorities and are grateful for their positive feedback and encouragement. At the same time, we are preparing for additional approvals to involve clinical centers in other European and Non-European countries,” said Dr. Rainer Lichtenberger, co-founder and CEO of Atriva. “After the recent financing and commitment from our investors, this authorization further enhances the clinical development program of ATR-002, the only host-targeted antiviral specifically developed to treat respiratory RNA virus infections.”

Prof. Martin Witzenrath, M.D., Vice Director Department of Infectious Diseases and Respiratory Medicine at Charité – Universitätsmedizin Berlin, Germany, will act as Global Coordinating Investigator. The study will be run at Charité and additional German and international clinical centers.

Explaining the significance of the study, Prof. Martin Witzenrath said: “There is an urgent need for an effective treatment to stop COVID-19 patients from progressing to critical conditions requiring intensive care and causing potentially permanent health issues and even death. ATR-002’s capability to both fight the virus and combat the excessive immune response that we see in patients with moderate or severe COVID-19 makes it a very promising therapeutic candidate for this patient population. We are confident that this pivotal study will quickly lead to an effective treatment for the patients most severely affected by this disease.”

“Starting a Phase II clinical trial with ATR-002 in patients suffering from COVID-19 is an important step for Atriva and we have every confidence in the expertise and support of the Charité medical team to lead this study. With this trial, we intend to rapidly advance our drug candidate so patients in need for therapeutic options can potentially benefit from it. Ultimately, our goal is to provide a safe antiviral that can help treat not only infections with SARS-CoV-2, but also influenza and future emerging RNA virus outbreaks,” concluded Dr. Martin Bauer, M.D., FNWC, Atriva’s Chief Medical Officer.

About ATR-002’s mode of action with dual benefit

The Atriva lead product ATR-002 is developed specifically to treat diseases such as influenza and COVID-19, caused by RNA viruses. ATR-002 is a clinical stage MEK inhibitor drug candidate targeting the intracellular Raf/MEK/ERK signaling pathway. This pathway is central for replication of many RNA viruses, such as the influenza virus, hantavirus or respiratory syncytial virus (RSV) and also SARS-CoV-2, the virus that causes COVID-19. In influenza virus infected cells, the interaction of ATR-002 with MEK (MAPK/ERK kinase) prevents export of the viral genome protein complexes (ribonucleoprotein, RNP) from the nucleus to the cytoplasm, thus blocking the formation of functional new viral particles. This ultimately reduces the viral load in the body.[4]

In addition, ATR-002 has the potential to modulate the pro-inflammatory cytokine response of the body, avoiding overshooting cytokine response that can be caused by such viral infections. MEK inhibition can reduce the gene expression of some of the cytokines involved, like TNF-α, IL-1ß, IP-10, IL-8, MCP-1 and MIP-1a, and thus mitigate the overactive inflammatory response in the lungs of patients who are severely ill with influenza or COVID-19.[5]

About Atriva Therapeutics GmbH

Atriva Therapeutics, founded in 2015, is a biopharmaceutical company pioneering the development of host-targeting antiviral therapies set up by a team of leading scientists in viral research and seasoned industry experts. The Company aims to develop a therapy platform to treat severe respiratory diseases induced by RNA viruses with a high unmet medical need, such as influenza and COVID-19. The Atriva lead product ATR-002 is a first-in-class host-targeting agent which inhibits viral replication in influenza and favorably modulates the body’s immune response. ATR-002 is under clinical development and has successfully completed a Phase I trial to demonstrate safety and tolerability in healthy subjects. The Company has obtained regulatory approval for a Phase II study to evaluate efficacy in hospitalized COVID-19 patients; a Phase II study in influenza is planned to start later in 2021. The Company owns eleven patent families with broad international coverage related to the use of MEK inhibitors and other kinase inhibitors for antiviral therapies. The patent life runs through 2041. Atriva Therapeutics is located in Tübingen and Frankfurt, Germany.

Atriva is a founding member of the BEAT-COV initiative. www.beat-cov.de

For further information, please visit www.atriva-therapeutics.com and follow us on LinkedIn and Twitter.

Contact:
Atriva Therapeutics GmbH

Dr. Rainer Lichtenberger, CEO
phone: +49 6196 56 11 698
mobile: +49 151 7443 3175
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media and Investor Relations:
MC Services AG

Eva Bauer / Raimund Gabriel
phone: +49 89 210 228 80
This email address is being protected from spambots. You need JavaScript enabled to view it.

[1]     RESPIRE – A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients with COVID-19
[2]     https://www.who.int/publications/i/item/covid-19-therapeutic-trial-synopsis.
[3]     https://doi.org/10.1016/j.healun.2020.03.012.
[4]     Pleschka S et al. Nat Cell Biol 2001 Feb 3:301-5; Planz O Antiviral Res 2013 Jun 98(3):457-68; Haasbach E et al. Antiviral Res 2017 Jun 142:178-4; Laure M et al. Antiviral Res 2020 Jun 178:104806.
[5]     Pinto R et al. Antiviral Res 2011 Oct 92(1):45-56; Planz O Antiviral Res 2013 Jun 98(3):457-68; Schräder T et al. Antiviral Res 2018 Sep 157:80-92.

BEAT COV logo

  • Sichere und hoch wirksame Medikamente sind dringend erforderlich, um COVID-19-Patienten zu versorgen und Krankenhäuser zu entlasten.
  • Impfstoffe schützen vor Erkrankung, aber bereits Erkrankte benötigen dringend Medikamente für eine gezielte Therapie von Symptomen und eine Verbesserung der Überlebenschancen. Es fehlt die zielgerichtete Förderung von in der Entwicklung bereits fortgeschrittenen Medikamenten zur Behandlung von COVID-19.
  • BEAT-COV (Biotech Emergency Alliance for Therapies against COVID-19) ist ein Zusammen­schluss von vier deutschen, mittelständischen Biotechnologieunternehmen mit erfolg­versprechenden COVID-19-Therapieansätzen in späten Phasen der klinischen Entwicklung.

Deutschland, 02. Dezember 2020 – „Wir können lebenswichtige Medikamente zur Behandlung von COVID-19-Patienten zur Verfügung stellen, aber wir benötigen signifikante Unterstützung bei der Finanzierung der Entwicklungs- und Produktionskosten – jetzt!“ Mit diesem dringenden Appell wendet sich BEAT-COV, die Biotech Emergency Alliance for Therapies against COVID-19, heute an Politik und Öffentlichkeit. Die Initiative der vier mittelständischen deutschen Biotechnologieunternehmen AiCuris Anti-infective Cures GmbH, Atriva Therapeutics GmbH, Immunic AG und InflaRx GmbH fordert von der Politik klare Entscheidungen zur Förderung therapeutischer Maßnahmen für COVID-19-Patienten.

„Die Anzahl schwer erkrankter Patienten ist hoch, ca. ein Viertel aller COVID-19-Patienten in Deutschland, die intensivmedizinisch behandelt werden mussten, versterben.[i] Das können wir nicht hinnehmen“, sagt Dr. Daniel Vitt, CEO von Immunic, Gräfelfing. „Derzeit gibt es keine zugelassenen Medikamente, die ausreichend wirksam sind und das Virus sowie die höchst unterschiedlichen Krankheitsverläufe und
-symptome adressieren. Ärzte haben daher nur begrenzte Möglichkeiten, um Menschenleben zu retten oder die Verweildauer im Krankenhaus deutlich zu reduzieren. Wir benötigen unterschiedliche Therapieoptionen und es besteht dringender Handlungsbedarf!“

Beitrag der deutschen Biotechnologieunternehmen ist immens – bei zukünftigen Impfstoffen und Medikamenten

Trotz Impfstoffen werden Menschen noch über viele Monate, vielleicht sogar Jahre, schwer an COVID-19 erkranken. Um die Tücken des Virus und seinen Einfluss auf das Immunsystem in den Griff zu bekommen, ist es unerlässlich, rasch sichere und wirksame Medikamente zur Verfügung zu stellen.

„Einige innovative Unternehmen haben schon sehr früh in diesem Pandemie-Jahr reagiert und Studien aufgesetzt, um die Wirksamkeit ihrer Medikamente gegen SARS-CoV-2 zu prüfen“, so Dr. Rainer Lichtenberger, Mitgründer und CEO von Atriva Therapeutics, Frankfurt am Main. „Erste, sehr ermutigende Ergebnisse haben uns in Anbetracht der dramatischen Situation sehr angespornt. Die Medikamentenkandidaten der BEAT-COV-Initiative sind in ihrer Entwicklung bereits weit fortgeschritten und erfolgversprechend. Als mittelständische Unternehmen sind wir und unsere Mitarbeiter dabei ein hohes Risiko und bis an die äußerste Grenze unserer Belastbarkeit gegangen.“

Hohe Kosten für klinische Spätphasenstudien und Produktion von Medikamenten für Mittelständler nicht alleine zu stemmen

Die Durchführung der klinischen COVID-19-Studien sowie die Herstellung von Medikamenten für den Markteintritt sind jedoch sehr kostenintensiv und können von den Unternehmen, die jeweils nur 20-70 Mitarbeiter und noch keine signifikanten Umsätze haben, nicht alleine gestemmt werden. Die bestehenden Finanzierungen der Unternehmen durch private Investoren, auf Life Sciences spezialisierte Venture Capital Fonds oder durch eine Börsennotierung waren für ihre ursprünglich geplanten Entwicklungsprogramme in unterschiedlichen Indikationen vorgesehen. Die Unternehmen sind ihrer wissenschaftlichen Expertise gefolgt und ins Risiko gegangen, um Therapieentwicklungen in Deutschland voranzutreiben – zur Behandlung von erkrankten und schwer kranken COVID-19-Patienten.

„Wir fordern daher eine finanzielle Unterstützung von Medikamentenentwicklungen und zwar für die Durchführung der zulassungsrelevanten Studien sowie für die Herstellung und Vorbereitung des Markteintritts der neuen Medikamente“, fasst Prof. Dr. med. Niels C. Riedemann, CEO und Gründer von InflaRx, Jena, den Vorstoß von BEAT-COV zusammen. „Wir wollen die notwendigen klinischen Studien schnellstmöglich zu Ende führen, um schwerkranken Patienten und den behandelnden Ärzten so schnell wie möglich wirksame Therapieoptionen anbieten zu können. In der aktuellen Situation – mit steigender Belegung der Intensivstationen, langen Liegezeiten und kaum wirklich wirksamen Medikamenten – müssen wir schnell handeln und bereits vor der Zulassung eines Medikaments mit dem Aufbau von Produktionskapazitäten und Marktvorbereitungen beginnen.“

Erhebliche finanzielle Ressourcen sind notwendig, um die neuen Medikamente auf ihre überlegene Wirksamkeit zu überprüfen, parallel zu produzieren und zur Zulassung zu bringen, um sie dann so schnell wie möglich an die Kliniken liefern zu können.

Gezielte Förderung erfolgversprechender Therapievorhaben – Auswahl durch Expertengremium

„Unsere Vorschläge gehen noch weiter: Wir empfehlen die Einrichtung eines Fonds in Höhe von 500 Mio. EUR bis 750 Mio. EUR zur Finanzierung von fortgeschrittenen und erfolgversprechenden Therapievorhaben“, ergänzt Dr. Holger Zimmermann, wissenschaftlicher Geschäftsführer von AiCuris, Wuppertal. „Eine interdisziplinäre Expertenkommission soll die therapeutischen Projekte im Hinblick auf eine schnelle Umsetzbarkeit zugunsten erkrankter Patienten evaluieren. Dieser Kommission sollten beispielsweise Fachleute aus Immunologie, Infektiologie und Intensivmedizin sowie Zulassungsexperten und Gesundheitsökonomen angehören.“

Gute Beispiele hierfür sind u.a. die BARDA (Biomedical Advanced Research and Development Authority)[ii] und die Initiative „Operation Warp Speed“[iii] in den USA, die binnen kürzester Zeit den Entwicklern von Impfstoffen und Medikamenten eine gemeinsame Plattform und über 10 Mrd. USD zur Verfügung gestellt haben. Davon entfallen auf die Therapien ca. 1 Mrd. USD.[iv]

„Wir sind stolz darauf, dass wir die Entwicklung unserer Wirkstoffe innerhalb kürzester Zeit so weit vorantreiben konnten und sind überzeugt, einen wichtigen Beitrag im Kampf gegen COVID-19 und dessen Auswirkungen leisten zu können. Wir wollen unsere Ressourcen weiter mit aller Kraft einsetzen, müssen jedoch die Risiken für unsere Unternehmen minimieren. Wir brauchen nun signifikante und umgehende Förderung sowie zügige und flexible Bearbeitungsprozesse – vergleichbar mit der sehr erfolgreichen Förderung der Impfstoffvorhaben durch die öffentliche Hand. Unser gemeinsames Ziel ist es, die Entwicklung zu beschleunigen und dringend benötigte Therapien schnell zu den Patienten zu bringen“, so die Initiatoren von BEAT-COV.

Über BEAT-COV

Die Biotech Emergency Alliance for Therapies against COVID-19 (BEAT-COV) ist ein Zusammenschluss von vier deutschen, mittelständischen Biotechnologieunternehmen mit erfolgversprechenden COVID-19-Therapieansätzen in späten Phasen der klinischen Entwicklung. Die Initiative fordert von der Politik klare Entscheidungen zur Förderung therapeutischer Maßnahmen zugunsten von COVID-19-Patienten. Die Entwicklung von Therapien verlangt große, kostenintensive Zulassungsstudien und eine teure Vorproduktion der Wirkstoffe. Daher fordert BEAT-COV eine signifikante Förderung zur Finanzierung von erfolgversprechenden Therapieoptionen, um späte Phasen der klinischen Entwicklung gezielt zu fördern und die Produktion, Zulassung und Markteinführung zu unterstützen. Dafür sind 500 Mio. EUR bis 750 Mio. EUR erforderlich. BEAT-COV wurde im Herbst 2020 von AiCuris Anti-infective Cures GmbH, Atriva Therapeutics GmbH, Immunic AG und InflaRx GmbH gegründet.

Weitere Informationen erhalten Sie unter www.beat-cov.de.

Über AiCuris Anti-infective Cures GmbH

AiCuris wurde 2006 als Spin-Off der Bayer AG gegründet und konzentriert sich auf die Erforschung und Entwicklung von Wirkstoffen gegen Infektionskrankheiten. Hauptinvestoren des Unternehmens sind die Dres. Strüngmann. Mit PREVYMIS™ (Letermovir) wurde ein “First-in-Class“ nicht-nukleosidischer Cytomegalovirus (CMV)-Inhibitor entwickelt, der seine Wirkung über einen neuartigen Wirkmechanismus entfaltet. Er wurde im Jahre 2012 an MSD auslizensiert und hat in der EU, den USA, Japan und in anderen Teilen der Welt die Marktzulassung zur Prävention von CMV-Infektionen bei erwachsenen Empfängern einer allogenen hämatopoetischen Stammzelltransplantation (HSCT) erhalten. Das Unternehmen entwickelt weitere Medikamente gegen Viren wie das Herpes-simplex-Virus (HSV), das Hepatitis-B-Virus (HBV) und Adenoviren. Im Bereich antibakterieller Wirkstoffe konzentriert AiCuris sich auf die Erforschung innovativer Behandlungsmöglichkeiten gegen lebensbedrohliche (multi‑) resistente Krankenhauserreger.

Im November 2018 wurden Dr. Holger Zimmermann, CEO von AiCuris, und Prof. Dr. Helga Rübsamen-Schaeff, Gründungs-CEO, für die Entwicklung von Letermovir und ihr Projekt „Schutz bei fehlendem Immunsystem – die lebensrettende Innovation gegen gefährliche Viren" mit dem Deutschen Zukunftspreis 2018 ausgezeichnet.

Weitere Informationen zum Unternehmen finden Sie unter www.aicuris.com. Folgen Sie uns auf LinkedIn.

Über Atriva Therapeutics GmbH

Atriva Therapeutics ist ein biopharmazeutisches Unternehmen, das die Entwicklung neuer anti­viraler Therapien gegen schwere Virusinfektionen der Atemwege, wie COVID-19 und Influenza, zum Ziel hat. Das 2015 gegründete Unter­nehmen wurde von einem Team führender Virologen und erfahrenen Branchenexperten aufgebaut und forscht in Indikationen mit hohem ungedecktem medizinischem Bedarf. Atriva konzentriert sich auf die Entwicklung einer Thera­pieplattform für neuartige Wirkstoffe, die eine Vermehrung von Viren hemmen, indem sie einen zellulären Faktor, der für die Weitergabe der Erbinformation von wesentlicher Bedeutung ist, blockieren und das Immunsystem modu­lieren. Das Lead-Produkt ATR-002 ist der erste Vertreter dieser neuen Wirkstoffklasse und befindet sich in klinischer Entwicklung; eine Phase I-Studie zur Bewertung der Sicherheit und Verträglichkeit wurde bereits erfolgreich abge­schlossen. Eine klinische Phase II-Studie zur Wirksamkeit bei COVID-19 ist in Vorbereitung; der Start einer Phase II-Studie bei Influenza ist für das zweite Halbjahr 2021 geplant. Atriva besitzt elf Patentfamilien, die umfassenden, internationalen Patentschutz zur Verwendung von MEK-Inhibitoren und anderen Kinase-Inhibitoren für antivirale Therapien gewähren und bis 2041 gelten. Atriva Therapeutics GmbH ist in Tübingen und Frankfurt am Main ansässig.

Für weitere Informationen besuchen Sie bitte www.atriva-therapeutics.com und folgen Sie uns bei LinkedIn und Twitter.

Über Immunic AG

Immunic (Nasdaq: IMUX) ist ein biopharmazeutisches Unternehmen, das über eine Pipeline von selektiven, oral verfügbaren Immunologie-Therapien zur Behandlung chronischer Entzündungs- und Autoimmunerkrankungen, wie schubförmig remittierende Multiple Sklerose, Colitis Ulcerosa, Morbus Crohn und Schuppenflechte, verfügt. Immunic entwickelt drei Small Molecule-Produkte: Das am weitesten fortgeschrittene Entwicklungsprogramm, IMU-838, ist ein selektiver Immunmodulator, der den intrazellulären Stoffwechsel von aktivierten Immunzellen hemmt, indem er das Enzym DHODH blockiert und der eine Wirtszell-basierte antivirale Wirkung zeigt; IMU-935 ist ein inverser Agonist von RORγt; und IMU-856 zielt auf die Wiederherstellung der intestinalen Barrierefunktion ab. Immunic gab positive Daten aus der Phase-2-Studie „EMPhASIS“ mit IMU-838 in schubförmig remittierender Multipler Sklerose bekannt, wobei sowohl der primäre als auch der wichtigste sekundäre Endpunkt mit hoher statistischer Signifikanz erreicht wurden. IMU-838 befindet sich außerdem in klinischen Phase-2-Studien zur Behandlung von Colitis Ulcerosa und COVID-19. Eine weitere Phase-2-Studie in Morbus Crohn ist geplant. An der Mayo Clinic wird zudem eine Prüfarzt-initiierte, klinische „Proof-of-Concept“-Studie mit IMU-838 in primär sklerosierender Cholangitis durchgeführt. Für weitere Informationen besuchen Sie bitte: www.imux.com.

Über InflaRx GmbH

InflaRx (Nasdaq: IFRX) ist ein biopharmazeutisches Unternehmen, das eine eigene Antikörpertechnologie (Vilobelimab, auch IFX-1) entwickelt hat, welche den menschlichen Komplementfaktor C5a in seiner biologischen Wirkung hoch effektiv und selektiv blockiert, um unkontrollierte schwere und lebensbedrohliche Entzündungserkrankungen zu behandeln. C5a ist Teil des Immunsystems und wirkt im Menschen als Verstärker einer großen Bandbreite von Entzündungs­prozessen. Diese Verstärkung kann die eigenen Gewebe angreifen und zum Organschaden führen. Neben anderen Indikationen steht der Einsatz von Vilobelimab zur Behandlung von durch COVID-19 ausgelöster viraler Sepsis und dem damit verbundenen Organversagen im Fokus der klinischen Entwicklung. InflaRx wurde 2007 in Jena gegründet und hat weitere Standorte in München sowie in Ann Arbor, MI, USA.

Für weitere Informationen besuchen Sie bitte www.inflarx.com.

Medienanfragen

MC Services AG
Katja Arnold
Telefon: +49-89-210228-0
This email address is being protected from spambots. You need JavaScript enabled to view it.

Warnhinweis zu zukunftsgerichteten Aussagen

Diese Pressemitteilung enthält zukunftsgerichtete Aussagen, die erhebliche Risiken und Unsicherheiten im Hinblick auf den „Safe Harbor“ des Private Securities Litigation Reform Act von 1995 beinhalten. Alle Aussagen, mit Ausnahme von Aussagen über historische Fakten, die in dieser Pressemitteilung über die Strategie, zukünftige Geschäftstätigkeiten, die zukünftige Finanzlage, die zukünftigen Einnahmen, geplante Ausgaben, Aussichten, Pläne und Ziele des Managements enthalten sind, sind zukunftsgerichtete Aussagen. Die genannten Unternehmen können möglicherweise nicht tatsächlich die Pläne erreichen, die Absichten umsetzen oder die Erwartungen oder Prognosen erfüllen, die in den zukunftsgerichteten Aussagen dargelegt werden, und Sie sollten sich nicht auf diese zukunftsgerichteten Aussagen verlassen. Solche Aussagen basieren auf den aktuellen Erwartungen des Managements und beinhalten Risiken und Unsicherheiten. Die tatsächlichen Ergebnisse und Leistungen können wesentlich von den in den zukunftsgerichteten Aussagen prognostizierten abweichen, und zwar aufgrund zahlreicher Faktoren, einschließlich, aber nicht beschränkt auf, die COVID-19-Pandemie, Risiken und Unsicherheiten im Zusammenhang mit der Fähigkeit, die zukünftige Mittelverwendung und die für zukünftige Verbindlichkeiten und Geschäftsaktivitäten erforderlichen Reserven vorherzusagen, der Verfügbarkeit ausreichender Finanzmittel, um Geschäftsziele und betrieblichen Anforderungen zu erfüllen, der Tatsache, dass die Ergebnisse früherer Studien und Prüfungen möglicherweise keine Vorhersagen über zukünftige Ergebnisse klinischer Studien treffen, dem Schutz und der Marktexklusivität des geistigen Eigentums, Risiken im Zusammenhang mit der Arzneimittelentwicklung und dem Zulassungsverfahren sowie den Auswirkungen von Wettbewerbsprodukten und technologischen Veränderungen. Eine weitere Auflistung und Beschreibung dieser Risiken, Unsicherheiten und anderer Faktoren finden Sie in den Einreichungen der Unternehmen bei der Securities and Exchange Commission. Kopien dieser Unterlagen sind online unter www.sec.gov oder auf den Webseiten der Unternehmen erhältlich. Jede zukunftsgerichtete Aussage in dieser Mitteilung ist nur auf den Zeitpunkt dieser Mitteilung bezogen. Die genannten Unternehmen lehnen jede Absicht oder Verpflichtung ab, diese zukunftsgerichteten Aussagen zu aktualisieren, um Ereignisse oder Umstände widerzuspiegeln, die nach dem Datum, an dem die Aussagen getroffen wurden, bestehen. Die genannten Unternehmen lehnen ausdrücklich jegliche Haftung für Handlungen ab, die auf der Grundlage des Gesamtinhalts oder eines Teils des Inhalts dieser Pressemitteilung vorgenommen wurden oder nicht vorgenommen wurden.

[i] https://diviexchange.blob.core.windows.net/%24web/DIVI_Intensivregister_Report.pdf
[ii]
https://www.medicalcountermeasures.gov/barda/
[iii]
https://www.hhs.gov/coronavirus/explaining-operation-warp-speed/index.html
[iv]
https://www.politico.com/news/2020/10/02/warp-speed-covid-antibody-treatments-425649

  • European Investment Bank and Atriva Therapeutics sign financing agreement of €24 million for the research, development and clinical testing of the company’s lead product candidate against influenza and COVID-19
  • Atriva’s ATR-002 molecule is the only host-cell targeting antiviral therapeutic specifically developed to treat severe respiratory infections caused by RNA (ribonucleic acid) viruses – it may prevent progression to critical-stage COVID-19 in hospitalised patients and holds strong potential in the current pandemic
  • The EIB venture debt transaction is financed under the Infectious Diseases Finance Facility set up as part of Horizon 2020, the EU research and innovation programme for 2014-2020

Germany, October 20, 2020 - The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses. RNA viruses cause diseases such as influenza, SARS and COVID-19. Atriva’s ATR-002, an oral small molecule, has been proven to block the viral propagation of SARS-CoV-2 in pre-clinical trials, making it a much-needed therapeutic option for patients with moderate to severe COVID-19 symptoms who require hospitalisation.

“While one needs to be careful when comparing COVID-19 to the flu, it might be helpful that both diseases have overlaps in their mechanisms of infection,” said Ambroise Fayolle, EIB Vice-President in charge of innovation and transactions in Germany. “If, as Atriva’s research indicates, one small molecule can work to treat both diseases, this would be excellent news not only for the millions of people who fall ill from the flu every year but also for the many more who are affected by the coronavirus lately. An effective treatment would also lift a huge burden from our health systems and help mitigate the impact these diseases have on our daily lives and the economy. This is a case where EIB financing can contribute to addressing an extremely high unmet medical need, which is something I am proud of.”

Mariya Gabriel, Commissioner for Innovation, Research, Culture, Education and Youth, said: “The European Union is doing all in its power to protect Europeans against coronavirus. The European Commission is coordinating the Coronavirus Global Response, the global action for universal access to tests, treatments and vaccines against coronavirus and for the global recovery. With this loan to Atriva, the EU continues its support for the development of innovative Covid-19 treatments. Their therapy can add to the range of complementary solutions that we need to tackle this disease.”

Dr Rainer Lichtenberger, co-founder and CEO of Atriva, said: “The EIB clearly understands the need for an effective antiviral therapy against influenza and COVID-19 and the potential such a treatment holds to help patients around the world. We are grateful for the EIB’s support in advancing the clinical development of ATR-002 as an innovative host-targeting therapy against these prevalent and potentially devastating diseases. With the funding from the EIB, we can now take the next development steps –starting a Phase II study in patients with moderate to severe COVID-19 infections, followed by further clinical development work in influenza.” He continued: “When the coronavirus pandemic hit us all earlier this year, we saw that Atriva’s technology had the potential to play an important role in the fight against COVID-19, and we are excited to move forward in this work now. Our ultimate goal, though, is to develop a broad-spectrum antiviral drug that will also be effective against future viral outbreaks.”

ATR-002 has been developed specifically to treat respiratory viral infections by inhibiting MEK, a host cell factor required for the replication of various RNA viruses, including the influenza virus and SARS-CoV-2. Atriva’s pre-clinical studies, performed at the Universities of Tübingen and Münster, have demonstrated that MEK inhibition by ATR-002 also prevents SARS-CoV-2 replication.

In addition to its antiviral efficacy, ATR-002 shows a second beneficial effect: the MEK-inhibitor was able to significantly decrease pro-inflammatory cytokine and chemokine expression in cells. Cytokines and chemokines are proteins that coordinate the immune response throughout the body. In patients with COVID-19, ATR-002 could prevent a cytokine storm and the associated disease progression to a life-threatening condition.

This dual benefit, antiviral activity and immunomodulation, positions ATR-002 as a promising therapeutic candidate. Atriva has filed the respective patents with the European Patent Office. In addition, ATR-002 successfully completed a Phase I clinical trial in 2019 where it demonstrated excellent safety and tolerability in healthy volunteers.

Atriva will receive the EIB loan in three tranches upon the completion of pre-defined milestones. The funds will support the company’s R&D for ATR-002, including clinical trial expenses, the technical transfer and manufacturing ramp-up needed to reach a commercial scale, as well as regulatory, intellectual property, pharmacovigilance and market access activities. Atriva will now start a multinational, double-blind, randomised clinical Phase II study in hospitalised patients with moderate to severe COVID-19 infections.

The loan is backed by the Infectious Diseases Finance Facility (IDFF) set up as part of the EU’s Horizon 2020 programme. The IDFF is an example of successful collaboration between the European Commission and the EIB in the face of a health crisis. Through this facility, the EIB has supported European companies with total lending of around €400 million for developing cures, vaccines and diagnostics for various infectious diseases, most prominently the coronavirus.

Background information

The European Investment Bank is the long-term lending institution of the European Union owned by its Member States. It makes long-term finance available for sound investments in order to contribute towards EU policy goals. The EIB also supports investments outside the EU.

The InnovFin Infectious Diseases Finance Facility (IDFF) is dedicated to supporting the fight against infectious diseases. This joint European Commission and EIB Group initiative is part of Horizon 2020, the 2014-2020 EU research and innovation programme. The IDFF enables the EIB to provide between €7.5m and €75m of funding to innovative players active in developing vaccines, drugs, medical and diagnostic devices and research infrastructure for combating infectious diseases. The financing mainly goes to projects that have completed the pre-clinical stage and need clinical approval for further development. The IDFF has been increased by €400 million to boost its capacity for tackling the outbreak of the coronavirus. The total EU contribution to the IDFF via Horizon 2020 is estimated at almost €700 million.

About Atriva Therapeutics GmbH

Atriva Therapeutics, founded in 2015, is a biopharmaceutical company specifically pioneering the development of host-targeting antiviral therapies set up by a team of leading scientists in viral research and seasoned industry experts. The company aims to develop new antiviral therapies against different severe respiratory viral infections with a high unmet medical need, such as influenza and COVID-19. Atriva’s lead product ATR-002 is a first-in-class host-targeting agent, which inhibits viral replication in influenza and favourably modulates the body’s immune response. ATR-002 is under clinical development and has successfully completed a Phase I trial to demonstrate safety and tolerability in healthy subjects (NCT04385420). The Company has initiated a Phase II study to evaluate efficacy in hospitalised COVID-19 patients while a Phase II study in influenza is planned to start in early 2021. Atriva Therapeutics is located in Tübingen and Frankfurt, Germany.

Press contacts

EIB
Antonie Kerwien
, This email address is being protected from spambots. You need JavaScript enabled to view it., Tel.: +352 691 285497
Website: www.eib.org/press - Press Office: +352 4379 21000 – This email address is being protected from spambots. You need JavaScript enabled to view it.

Atriva Therapeutics GmbH
Dr Rainer Lichtenberger
, CEO, tel. +49 6196 56 11 698/ Mobile: +49 6196 56 11 698
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media and Investor Relations: MC Services AG
Eva Bauer / Raimund Gabriel, tel.: +49 89 210 228 80   This email address is being protected from spambots. You need JavaScript enabled to view it.

  • Round led by existing investors Meneldor and High-Tech Gründerfonds
  • Proceeds to be used to start Phase II study with ATR-002 in moderate to severe COVID-19 and clinical development in influenza and other respiratory viral infections
  • ATR-002 mode of action inhibits viral propagation of respiratory RNA viruses and prevents the cytokine storm, as demonstrated in preclinical studies

Tübingen (Germany), August 11, 2020 – Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the closing of a € 8.6 million ($ 10.2 million) convertible loan led by Meneldor B.V. and High-Tech Gründerfonds (HTGF), and joined by existing shareholders and new German and international investors.

The proceeds of the transaction will enable Atriva to start a multinational, double-blind, randomized clinical Phase II study[1] in patients with moderate to severe COVID-19 infections, once authorization is granted by the German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM). It will further be used to prepare a Phase II trial in influenza and to continue building a therapy platform to treat respiratory diseases induced by RNA viruses, such as Hantavirus. ATR-002 has been developed specifically to treat respiratory viral infections by inhibiting MEK, a host cell factor required for the replication of various RNA viruses, including influenza virus and SARS-CoV-2.

Preclinical studies demonstrated that MEK inhibition by ATR-002 inhibits SARS-CoV-2 replication and significantly decreases pro-inflammatory cytokine and chemokine expression in human cells and in an animal model of acute lung injury (ALI). These preclinical studies show that ATR-002 could prevent a cytokine storm and the associated disease progression to a life-threatening condition, such as observed in patients with COVID-19.

“The strong belief in the science on which Atriva was built, combined with drive and endurance of Atriva’s management team made Meneldor decide to continue investing in this vital technology. Congratulations to the team. With confidence we look forward to the further development of the company and especially now of the clinical development of Atriva’s programs,” said Paul Lelieveld, Founding Partner, Meneldor, The Netherlands. “In scientific and medical terms, this therapy approach holds great promise for COVID-19 patients and doctors, until there is broad access to vaccines that can work for everyone worldwide. ATR-002, according to our analysis, has great potential in this approach and potentially also for other RNA virus-related diseases,” noted Frans van Dalen, Founding Partner, Meneldor, The Netherlands.

“The recent preclinical studies as well as the Phase I study completed in 2019 give us great faith that ATR-002 will be able to fulfill the urgent need for an effective COVID-19 therapy,” said Dr. Frank Hensel, Principal of High-Tech Gründerfonds (HTGF, Germany). “The mode of action of this oral therapy approach certainly differentiates it from other therapies, currently in development. We believe this technology has a high potential for success and could still address other rapidly spreading viral infections of the respiratory tract. Furthermore, it will be a pleasure to continue working alongside the Atriva team through these urgently needed Phase II trials and potentially see the regulatory approval for this orally available small molecule MEK inhibitor.”

“With such highly committed investors continuing to support our plans we will now focus on ramping-up this important pivotal Phase II trial to treat patients with moderate to severe COVID-19,” said Dr. Rainer Lichtenberger, co-founder and CEO of Atriva. “This transaction is connected to additional ongoing financing activities which will support Atriva all the way through completion of two Phase II programs in COVID-19 and influenza.”

About ATR-002’s mode of action with dual benefit

Atriva’s lead product ATR-002 is developed specifically to treat diseases such as influenza and COVID-19, caused by RNA viruses. ATR-002 is a clinical stage MEK inhibitor drug candidate targeting the intracellular Raf/MEK/ERK signaling pathway. This pathway is central for replication of many RNA viruses, such as the influenza virus, hantavirus or respiratory syncytial virus (RSV) and also SARS-CoV-2, the virus that causes COVID-19. In influenza virus infected cells, the interaction of ATR-002 with MEK (MAPK/ERK kinase) prevents export of the viral genome protein complexes (ribonucleoprotein, RNP) from the nucleus to the cytoplasm, thus blocking the formation of functional new viral particles. This ultimately reduces the viral load in the body.[2]

In addition, ATR-002 has the potential to modulate the pro-inflammatory cytokine response of the body, avoiding overshooting cytokine response that can be caused by such viral infections. MEK inhibition can reduce the gene expression of some of the cytokines involved, like TNF-α, IL-1ß, IP-10, IL-8, MCP-1 and MIP-1a, and thus mitigate the overactive inflammatory response in the lungs of patients who are severely ill with influenza or COVID-19.[3]

About Atriva Therapeutics GmbH

Atriva Therapeutics, founded in 2015, is a biopharmaceutical company pioneering the development of host-targeting antiviral therapies set up by a team of leading scientists in viral research and seasoned industry experts. The Company aims to develop a therapy platform to treat severe respiratory diseases induced by RNA viruses with a high unmet medical need, such as influenza and COVID-19. Atriva’s lead product ATR-002 is a first-in-class host-targeting agent which inhibits viral replication in influenza and favorably modulates the body’s immune response. ATR-002 is under clinical development and has successfully completed a Phase I trial to demonstrate safety and tolerability in healthy subjects. A Phase II study to evaluate efficacy in hospitalized COVID-19 patients is in preparation; a Phase II study in influenza is planned to start in early 2021. The Company owns eleven patent families with broad international coverage related to the use of MEK inhibitors and other kinase inhibitors for anti-viral therapies. The patent life runs through 2041. Atriva Therapeutics is located in Tübingen and Frankfurt, Germany.

For further information, please visit www.atriva-therapeutics.com and follow us on LinkedIn and Twitter.

Contact:
Atriva Therapeutics GmbH

Dr. Rainer Lichtenberger, CEO

phone: +49 6196 56 11 698
mobile: +49 151 7443 3175

This email address is being protected from spambots. You need JavaScript enabled to view it.

Media and Investor Relations:
MC Services AG

Eva Bauer / Raimund Gabriel
phone: +49 89 210 228 80
This email address is being protected from spambots. You need JavaScript enabled to view it.

 About Meneldor

Meneldor is an investment fund, focused on early stage biotech and pharma companies that (re)develop (New) Biological or Chemical Molecular Entities, that have outstanding technology with strong IP, address significant unmet medical needs and attractive markets. Meneldor scouts especially for companies that work on relatively low risk and high growth opportunities, and mainly invests in projects which are in preclinical, Phase I or Phase II and in indications with preferably clear well-defined clinical endpoints. Meneldor’s geographic focus is Western Europe.

Contact:

Ir. Paul Lelieveld
Van Heemstraweg 123d
6651 KH Druten, The Netherlands
phone: +31-6 46 23 23 57
This email address is being protected from spambots. You need JavaScript enabled to view it.

About High-Tech Gründerfonds

High-Tech Gründerfonds (HTGF) is a seed investor that finances high-potential, tech-driven start-ups. With around EUR 900 million in total investment volume across three funds and an international network of partners, HTGF has already helped forge almost 600 start-ups since 2005. Driven by their expertise, entrepreneurial spirit and passion, its team of experienced investment managers and startup experts help guide the development of young companies. HTGF’s focus is on high-tech start-ups in the fields of digital tech, industrial technology, life sciences, chemistry and related business areas. To date, external investors have injected over EUR 2.5 billion into the HTGF portfolio via more than 1,600 follow-on financing rounds. HTGF has also successfully sold interests in more than 100 companies.

Investors in this public-private partnership include the Federal Ministry For Economic Affairs and Energy, KfW Capital, and Fraunhofer-Gesellschaft e.V., as well as the companies ALTANA, BASF, BAYER, B.Braun, Boehringer Ingelheim, Robert Bosch, BÜFA, CEWE, Deutsche Post DHL, Dräger, Drillisch AG, EVONIK, EWE AG, FOND OF, Haniel, Hettich, Knauf, Körber, LANXESS, media + more venture Beteiligungs GmbH & Co. KG, PHOENIX CONTACT, Postbank, QIAGEN, RWE Generation SE, SAP, Schufa, Schwarz Gruppe, STIHL, Thüga, Vector Informatik, WACKER and Wilh. Werhahn KG.

Contact:

High-Tech Gründerfonds Management GmbH
Dr. Frank Hensel
Schlegelstr. 2
53113 Bonn, Germany
phone: +49 228 82300 100
This email address is being protected from spambots. You need JavaScript enabled to view it.
www.htgf.de/en/

[1]    https://www.atriva-therapeutics.com/news/14-news/96-news-phase2-2020

[2]     Pleschka S et al. Nat Cell Biol 2001 Feb 3:301-5; Planz O Antiviral Res 2013 Jun 98(3):457-68; Haasbach E et al. Antiviral Res 2017 Jun 142:178-4; Laure M et al. Antiviral Res 2020 Jun 178:104806.

[3]     Pinto R et al. Antiviral Res 2011 Oct 92(1):45-56; Planz O Antiviral Res 2013 Jun 98(3):457-68; Schräder T et al. Antiviral Res 2018 Sep 157:80-92.

Contact Form

Please, enter your name
Please, enter your phone number
Please, enter your e-mail address Mail address is not not valid
Please, enter your message

Address

Atriva Therapeutics GmbH
Eisenbahnstr. 1, 72072 Tübingen

+49 (0)7071 8597673
info@atriva-therapeutics.com

LinkedIn
Twitter

In order to be able to design our website in the best possible way and to continuously improve it, we are using cookies. By continuing to use our website, you permit the use of cookies. More information can be found in our data protection rules.